Stock comparison
Halozyme Therapeutics
InMode
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
INMD
InMode
Market cap
$870.55M
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | INMD | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 56C | HALO |
| Benjamin Graham | 83A | 52C | HALO |
| Philip Fisher | 65B | 46D | HALO |
| Peter Lynch | 53D | 24F | HALO |
| Joel Greenblatt | 40D | 27F | HALO |
| Charlie Munger | 80C | 58C | HALO |
| Terry Smith | 84A | 59C | HALO |
Side-by-side metrics
| Metric | HALO | INMD |
|---|---|---|
| Market cap | $8.1B | $870.55M |
| P/E (TTM) | 24.0x | 10.0x |
| EV/EBIT | 10.2x | 5.6x |
| ROIC (TTM) | 23.65% | 10.11% |
| Gross margin | 81.24% | 77.84% |
| Net margin | 23.13% | 23.27% |
| Revenue CAGR 5y | 33.23% | 0.89% |
| EPS CAGR 5y | -1.98% | -8.07% |
| Debt / Equity | 1.0x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 0.89%+97%
- Market cap$8.1Bvs $870.55M+89%
- EPS CAGR 5y-1.98%vs -8.07%+75%
- ROIC (TTM)23.65%vs 10.11%+57%
INMD leads on
- Debt / Equity0.0xvs 1.0x+99%
- P/E (TTM)10.0xvs 24.0x+58%
- EV/EBIT5.6xvs 10.2x+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.